Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Solid Tumors 4Advanced Solid Tumors 4Solid Tumor 3Mesothelioma 3Advanced Solid Tumor 3Advanced Solid Tumours 2Thymoma 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Malignant Solid Tumors 1Lung Neoplasms 1Advanced Solid Tumor, Adult 1Advanced Cancer 1

Interventions

adavosertib 5durvalumab 3Paclitaxel 3olaparib 2ceralasertib 2Fluorouracil 2Carboplatin 2toripalimab 1sintilimab 1pembrolizumab 1factor IX, factor VII, factor X, prothrombin drug combination 1drug XX Z 1danvatirsen 1capivasertib 1Rifampin 1Pantoprazole 1Omeprazole 1Leucovorin 1Itraconazole 1Irinotecan 1Injections 1Gemcitabine 1Doxorubicin 1Cisplatin 1AZD0156 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Solid Tumours × olaparib × Other solid neoplasm × Clear all
NCT02588105 2022-09-19

AToM

AstraZeneca

Phase 1 Completed
84 enrolled
Other solid neoplasm

Advanced Solid Tumours

NCT02430311 2019-07-31

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

AstraZeneca

Phase 1 Completed
36 enrolled 24 charts
Other solid neoplasm

Advanced Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡